Levetiracetam in generalized social anxiety disorder: A double-blind, randomized controlled trial

Journal of Clinical Psychiatry

Volumn 71, Issue 5, 2010, Pages 627-631

  Stein, Murray B ^a   Ravindran, Lakshmi N ^b   Simon, Naomi M ^c   Liebowitz, Michael R ^d   Khan, Arifulla ^e   Brawman Mintzer, Olga ^f   Lydiard, R Bruce ^g   Pollack, Mark H ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e Northwest Clinical Research Center   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g Southeast Health Consultants LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; GENERALIZED ANXIETY DISORDER; GENERALIZED SOCIAL ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATION; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHOBIC DISORDERS; PIRACETAM; PSYCHIATRIC STATUS RATING SCALES;

EID: 77952623017     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04949gre     Document Type: Article

References (21)

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. (Pubitemid 40973434)
2. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100(3):193-198. PubMed doi:10.1/j.160-047.19.tb10845.x 3. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156(5):756-760. (Pubitemid 29409085)
3. Blanco C, Raza MS, Schneier FR, et al. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol. 2003;6(4):427-442. (Pubitemid 38146264)
4. Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341-348. (Pubitemid 29344848)
5. Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141-149.
6. Van Ameringen M, Mancini C, Pipe B, et al. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry. 2004;65(12):1674-1678.
7. Farooq MU, Bhatt A, Majid A, et al. Levetiracetam for managing neurologic and psychiatric disorders. Am J Health Syst Pharm. 2009;66(6):541-561.
8. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42 (suppl 4):24-27.
9. Custer KL, Austin NS, Sullivan JM, et al. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci. 2006;26(4):1303-1313.
10. Moroz G. High-potency benzodiazepines: recent clinical results. J Clin Psychiatry. 2004;65(suppl 5):13-18.
11. Kavoussi R. Pregabalin: from molecule to medicine. Eur Neuropsychopharmacol. 2006;16(suppl 2):S128-S133.
12. Kinrys G, Worthington JJ, Wygant L, et al. Levetiracetam as adjunctive therapy for refractory anxiety disorders. J Clin Psychiatry. 2007;68(7):1010-1013. (Pubitemid 47340319)
13. Kinrys G, Wygant LE, Pardo TB, et al. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry. 2006;67(2):211-214. (Pubitemid 43357466)
14. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry. 2006;67(10):1573-1576.
15. Simon NM, Worthington JJ, Doyle AC, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004;65(9):1219-1222.
16. Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005;19(5): 551-553. (Pubitemid 41392309)
17. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33. (Pubitemid 29001829)
18. Heimberg RG, Horner KJ, Juster HR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. 1999;29(1):199-212. (Pubitemid 29034537)
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
20. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health;1976:218-222.
21. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11(suppl 3):89-95.